Industry News
Gilvetmab, which previously received conditional license approval for the treatment of dogs with mast cell tumors and for treatment of dogs with melanoma, is now available to board-certified veterinary oncologists across the United States.
Gilvetmab is a caninized monoclonal antibody used to treat dogs with MCTs and melanomas. It is an ideal systemic treatment option labeled for dogs with stage I, II, and III MCTs and stage II and III melanomas.
Source: Merck Animal Health, October 13, 2023. Link. Gilvetmab will be administered by board-certified veterinary oncologists. Additionally, The Gilvetmab Product Grant Program provides support to boarded oncologists seeking to better understand the role of Merck Animal Health’s conditionally licensed gilvetmab in various clinical scenarios.